Zishenqing ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04275193 (ClinicalTrials.gov) | October 22, 2019 | 12/2/2020 | The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus | The Safety and Efficacy of the Traditional Chinese Medicine Zishenqing in Subjects With Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: Zishenqing;Drug: Placebo | Shanghai University of Traditional Chinese Medicine | RenJi Hospital | Recruiting | 18 Years | 65 Years | All | 118 | Phase 2/Phase 3 | China |